Compare IMCC & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCC | PRPO |
|---|---|---|
| Founded | 1980 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 32.4M |
| IPO Year | N/A | N/A |
| Metric | IMCC | PRPO |
|---|---|---|
| Price | $1.41 | $23.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 286.1K | 8.8K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,606,703.00 | $22,800,000.00 |
| Revenue This Year | $47.12 | N/A |
| Revenue Next Year | $12.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.92 | ★ 30.95 |
| 52 Week Low | $0.93 | $3.90 |
| 52 Week High | $7.12 | $28.50 |
| Indicator | IMCC | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 53.04 |
| Support Level | $1.35 | $22.10 |
| Resistance Level | $1.61 | $25.03 |
| Average True Range (ATR) | 0.24 | 1.20 |
| MACD | -0.03 | -0.26 |
| Stochastic Oscillator | 17.81 | 50.76 |
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.